Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 16/20 | 0.57 |
| ▸ | RAB9A | P51151 | 15/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 7/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16231622 | 0.92 | CEPT1 (0.54) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL13494491 | 0.87 | SMN1; SMN2 (0.51) | NPC1RAB9AMEN1KMT2ACEPT1 | |
| SCHEMBL7298455 | 0.85 | CEPT1 (0.52) | NPC1RAB9ACEPT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14669304 | 0.84 | CEPT1 (0.47) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL24871289 | 0.84 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL9820032 | 0.84 | UTRN (0.54) | NPC1RAB9ACEPT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4584419 | 0.84 | CEPT1 (0.49) | NPC1RAB9AMEN1KMT2ACEPT1 | |
| SCHEMBL6399187 | 0.83 | NPC1 (0.60) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL31154363 | 0.83 | NPC1 (0.63) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL5361789 | 0.83 | CEPT1 (0.48) | NPC1RAB9AMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210395242-A1 | HETEROCYCLIC COMPOUNDS AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2021-12-23 | — | — | US | disclosed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-3153501-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | disclosed |
| EP-2799428-A2 | Glucagon antagonists | Metabasis Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2799428-A2 | Glucagon antagonists | Metabasis Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2326618-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2326618-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| EP-2326618-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010019830-A1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019830-A1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030029-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | NPC1 830/4885RAB9A 2162/4885MEN1 1986/4885 |
| US-20210395242-A1 | HETEROCYCLIC COMPOUNDS AS AHR MODULATORS | AHR, ARNT, AIPL1 | NPC1 1455/4885RAB9A 509/4885MEN1 3336/4885 |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | NPC1 830/4885RAB9A 2162/4885MEN1 1986/4885 |
| US-20190099391-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | NPC1 887/4885RAB9A 2260/4885MEN1 1962/4885 |
| US-11352321-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | NPC1 830/4885RAB9A 2162/4885MEN1 1986/4885 |
| US-10221130-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | NPC1 887/4885RAB9A 2260/4885MEN1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.